Balentine LLC’s Idexx Laboratories IDXX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-402
| Closed | -$216K | – | 240 |
|
|
2025
Q2 | $216K | Sell |
402
-1,169
| -74% | -$559K | 0.01% | 155 |
|
|
2025
Q1 | $660K | Buy |
+1,571
| New | +$682K | 0.03% | 94 |
|
|
2024
Q2 | – | Sell |
-2,471
| Closed | -$1.33M | – | 360 |
|
|
2024
Q1 | $1.33M | Buy |
2,471
+773
| +46% | +$422K | 0.04% | 145 |
|
|
2023
Q4 | $942K | Buy |
1,698
+242
| +17% | +$114K | 0.03% | 179 |
|
|
2023
Q3 | $637K | Buy |
1,456
+32
| +2% | +$16K | 0.02% | 222 |
|
|
2023
Q2 | $715K | Buy |
1,424
+52
| +4% | +$24.9K | 0.02% | 218 |
|
|
2023
Q1 | $686K | Buy |
1,372
+12
| +0.9% | +$5.74K | 0.02% | 254 |
|
|
2022
Q4 | $555K | Buy |
1,360
+195
| +17% | +$75.7K | 0.02% | 312 |
|
|
2022
Q3 | $380K | Sell |
1,165
-99
| -8% | -$36.4K | 0.01% | 342 |
|
|
2022
Q2 | $443K | Buy |
1,264
+150
| +13% | +$61.2K | 0.02% | 341 |
|
|
2022
Q1 | $609K | Buy |
1,114
+322
| +41% | +$169K | 0.02% | 257 |
|
|
2021
Q4 | $522K | Buy |
792
+66
| +9% | +$41.4K | 0.02% | 163 |
|
|
2021
Q3 | $451K | Buy |
726
+43
| +6% | +$28.9K | 0.02% | 129 |
|
|
2021
Q2 | $431K | Buy |
683
+83
| +14% | +$45.8K | 0.02% | 93 |
|
|
2021
Q1 | $294K | Hold |
600
| – | – | 0.01% | 111 |
|
|
2020
Q4 | $300K | Sell |
600
-11
| -2% | -$4.92K | 0.01% | 103 |
|
|
2020
Q3 | $240K | Sell |
611
-20
| -3% | -$7.39K | 0.01% | 107 |
|
|
2020
Q2 | $208K | Buy |
631
+9
| +1% | +$2.61K | 0.01% | 98 |
|
|
2020
Q1 | $151K | Sell |
622
-155
| -20% | -$40.5K | 0.01% | 84 |
|
|
2019
Q4 | $203K | Sell |
777
-2,726
| -78% | -$718K | 0.01% | 73 |
|
|
2019
Q3 | $953K | Sell |
3,503
-24
| -0.7% | -$6.68K | 0.06% | 31 |
|
|
2019
Q2 | $971K | Sell |
3,527
-20
| -0.6% | -$4.93K | 0.06% | 27 |
|
|
2019
Q1 | $796K | Sell |
3,547
-82
| -2% | -$16.9K | 0.06% | 40 |
|
|
2018
Q4 | $675K | Buy |
3,629
+2,647
| +270% | +$543K | 0.05% | 50 |
|
|
2018
Q3 | $245K | Buy |
+982
| New | +$238K | 0.02% | 24 |
|
|
2018
Q1 | – | Sell |
-3,094
| Closed | -$484K | – | 267 |
|
|
2017
Q4 | $484K | Hold |
3,094
| – | – | 0.04% | 67 |
|
|
2017
Q3 | $481K | Sell |
3,094
-307
| -9% | -$48.5K | 0.04% | 58 |
|
|
2017
Q2 | $549K | Hold |
3,401
| – | – | 0.05% | 45 |
|
|
2017
Q1 | $526K | Sell |
3,401
-1,929
| -36% | -$266K | 0.05% | 41 |
|
|
2016
Q4 | $625K | Hold |
5,330
| – | – | 0.07% | 28 |
|
|
2016
Q3 | $601K | Buy |
+5,330
| New | +$562K | 0.08% | 32 |
|
Other funds holding IDXX
Balentine LLC's IDXX Position: Q3 2025 in Review
Balentine LLC sold out of Idexx Laboratories (IDXX) in Q3 2025, closing a stake of 402 shares — an estimated $216K sold.
Balentine LLC first reported a position in IDXX in Q3 2016 and held it in 31 quarters. The position peaked at $1.33M in Q1 2024. 1,302 funds tracked by Wall St. Rank hold IDXX as of Q3 2025.
- Balentine LLC reported no remaining Idexx Laboratories position as of Q3 2025 after selling out during the quarter.
- Balentine LLC sold 402 Idexx Laboratories shares in Q3 2025, an estimated $216K.
- Balentine LLC first reported a position in Idexx Laboratories in Q3 2016 and held it in 31 quarters.
- Balentine LLC's Idexx Laboratories position peaked at $1.33M in Q1 2024.
- 1,302 funds tracked by Wall St. Rank held Idexx Laboratories as of Q3 2025.
Based on Balentine LLC's 13F filing for Q3 2025, filed 7 Nov 2025.